ABSTRACT WATCH: Cytokines and the Brain: Implications for Clinical Psychiatry

Am J Psychiatry 157:683-694, May 2000
© 2000 American Psychiatric Association

Reviews and Overviews

Cytokines and the Brain: Implications for Clinical Psychiatry

Ziad Kronfol, M.D., and Daniel G. Remick, M.D.


OBJECTIVE: This article reviews recent developments in cytokine biology that are relevant to clinical psychiatry.METHOD: The authors reviewed English-language literature of the last 15 years that pertains to the biology of cytokines with emphasis on central nervous system effects in general and psychiatric disorders in particular.RESULTS: Growing evidence suggests that, in addition to providing communication between immune cells, specific cytokines play a role in signaling the brain to produce neurochemical, neuroendocrine, neuroimmune, and behavioral changes. This signaling may be part of a generalized, comprehensive mechanism to mobilize resources in the face of physical and/or psychological stress and to maintain homeostasis. The clinical implications of these findings are far-reaching and include a possible role for cytokines in the pathophysiology of specific psychiatric disorders such as major depression, schizophrenia, and Alzheimer’s disease. The effects of cytokines in the central nervous system may provide a possible mechanism for the “sickness behavior” of patients with severe infection or cancer, as well as for the neuropsychiatric adverse effects of treatment with interferons and interleukins.


A better understanding of the role of cytokines in various brain activities will enhance knowledge of specific psychobiological mechanisms in health and disease and provide opportunities for novel treatment interventions.


  1. Rothwell NJ (ed): Cytokine in the Nervous System. Georgetown, Tex, PG Landes, 1996
  2. Ransohoff RM, Benveniste EN (eds): Cytokines and the CNS. Boca Raton, Fla, CRC Press, 1996
  3. Plotnikoff N, Murgo A, Faith R, Good R (eds): Cytokines: Stress and Immunity. Boca Raton, Fla, CRC Press, 1999
  4. Kunkel SL, Remick DG (eds): Cytokines in Health and Disease. New York, Marcel Dekker, 1992
  5. Baggiolin M, Dewald B, Moser B: Human chemokines: an update. Annu Rev Immunol 1997; 15:675–705
  6. Licinio L, Kling M, Hauser P: Cytokines and brain function: relevance of interferon a-induced mood and cognitive changes. Semin Oncol 1998; 25:30–38
  7. Lin JS, Amaral TD, Brosnan CF, Lee SC: Interferons as critical regulators of IL-1 receptor antagonist and IL-1 expression in human microglia. J Immunol 1998; 16:1989–1996
  8. Breder CD, Tsujimoto M, Terano Y, Scott DW, Saper CB: Distribution and characterization of tumor necrosis factor-alpha-like immunoreactivity in the murine central nervous system. J Compr Neurol 1993; 337:543–567
  9. Bethea JR, Chung IY, Sparacio SM, Gillespie GY, Beneveniste EN: Interleukin-1b induction of tumor necrosis factor-alpha gene expression in human astroglioma cells. J Neuroimmunol 1992; 36:179–191
  10. Juul SE, Anderson DK, Li Y, Christensen RD: Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998; 43:40–49
  11. Tweardy D, Mott P, Glazer E: Monokine modulation of human astroglial cell production of granulocyte colony-stimulating factor and granulocyte-macrophage colony stimulating factor, I: effects of IL-1a and IL-1b. J Immunol 1990; 144:2233–2241
  12. Breder CD, Dinarello CA, Saper CB: Interleukin-1 immunoreactive innervation of the human hypothalamus. Science 1988; 240:321–324
  13. Rothwell NJ, Luheshi G: Pharmacology of interleukin-1 actions in the brain. Adv Pharmacol 1994; 25:1–20
  14. Hanisch UK, Quirion R: Interleukin-2 as a neuroregulatory cytokine. Brain Res Brain Res Rev 1995; 21:246–284
  15. Konishi Y, Chui DH, Kunishita T, Yamemura T, Higashi Y, Tabira T: Demonstration of interleukin-3 receptor-associated antigen on the central nervous system. J Neurosci Res 1995; 41:572–582
  16. Racke MK, Burnett D, Pak SH, Albert PS, Camella B, Raine CS, McFarlin DE, Scott DE: Retinoid treatment of experimental allergic encephalomyelitis: IL-4 production correlates with improved disease course. J Immunol 1995; 154:450–451
  17. Saweda N, Suzumura A, Itoh Y, Marunouchi T: Production of interleukin 5 by mouse astrocytes and microglia in culture. Neurosci Lett 1993; 155:175–178
  18. LeMay LB, Vander AJ, Kluger MJ: The effects of psychological stress on plasma interleukin-6 activity in rats. Physiol Behav 1990; 47:957–961
  19. Benveniste EN, Sparacia SM, Norris JG, Grenott HE, Muller GM: Induction and regulation of interleukin-6 gene expression in rat astrocytes. J Neuroimmunol 1990; 30:201–212
  20. Ehrlich LC, Hu S, Sheng WS, Sutton RC, Rocks-Wolf GC, Peterson PK, Chao CC: Cytokine regulation of human microglia cell IL-8 production. J Immunol 1998; 160:1944–1948
  21. Wong ML, Bongiorno PB, Rettori V, McCann SM, Licinio J: Interleukin-1 beta, interleukin-1 receptor antagonist, IL-10 and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. Proc Natl Acad Sci USA 1997; 94:227–232
  22. Elenkov I, Papanicolaon D, Wilder R, Chrousos GP: Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc Assoc Am Physicians 1996; 108:334–381
  23. Stalder AK, Pagenstecher A, Yu NC, Kincaid C, Chiang CG, Hobbs MV, Bloom FE, Campbell IL: Lipopolysaccharide-induced IL-12 expression in the central nervous system and cultured astrocytes and microglia. J Immunol 1997; 159:1344–1351
  24. Thompson A (ed): The Cytokine Handbook, 3rd ed. San Diego, Academic Press, 1998
  25. Mosmann TR, Coffman RL: TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145–173
  26. Hurme M, Lahdenpohja N, Santtila S: Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases. Ann Med 1998; 30:469–473
  27. Wilson AG, di Giovine FS, Duff GW: Genetics of tumour necrosis factor alpha in autoimmune, infectious, and neoplastic diseases. J Inflamm 1995; 45:1–12[
  28. Mira J-P, Cariou A, Grall F, Delclaux C, Losser M-R, Heshmati F, Cheal C, Monchi M, Teboul J-L, Riché F, Leleu G, Arbibe L, Mignon A, Delpech M, Dhainaut J-F: Association of TNF2, a TNF-{alpha} promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999; 282:561–568
  29. Smeraldi E, Sanardi R, Benedetti F, DiBella D, Perez J, Catalano M: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3:508–511
  30. Remick DG: Quantitation of cytokines, in Cytokines in Health and Disease, 2nd ed. Edited by Remick DG, Friedland JS. New York, Marcel Dekker, 1997, pp 281–298
  31. Cserr HF, Knopf PM: Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today 1992; 13:507–512
  32. Watkins LR, Maier SF, Goehler LE: Cytokine-to-brain communication: a review and analysis of alternative mechanisms. Life Sci 1995; 57:1011–1026
  33. Freidin M, Bennett MVL, Kessler JA: Cultured sympathetic neurons synthesize and release the cytokine interleukin-1b. Proc Natl Acad Sci USA 1992; 89:10440–10443
  34. Dinarello C: Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1988; 16:457–499
  35. Weiss JM, Sundar SK, Becker KJ, Cierpial MA: Behavioral and neural influences on cellular immune responses: effects of stress and interleukin-1. J Clin Psychiatry 1989; 50:43–53
  36. Romero LI, Kakueska I, Lechan RM, Reichlin S: Interleukin-6 (IL-6) is secreted from the brain after intracerebroventricular injection of IL-1 beta in rats. Am J Physiol 1996; 270:R518–R524
  37. Giulian D, Woodward J, Young DG, Krebs JF, Lachman LB: Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci 1988; 8:2485–2490
  38. Besedovsky H, del Rey A, Sorkin E, Da Prada M, Burri R, Honegger C: The immune response evokes changes in brain noradrenergic neurons. Science 1983; 221:564–566
  39. Dunn AJ, Powell ML, Meitin C, Small PA Jr: Virus infection as a stressor: influenza virus elevates plasma concentrations of corticosterone, and brain concentrations of MHPG and tryptophan. Physiol Behav 1989; 45:591–594
  40. Dunn AJ, Wang J: Cytokine effects on CNS biogenic amines. Neuroimmunomodulation 1995; 2:319–328
  41. Besedovsky H, Sorkin E, Keller M, Müller J: Changes in blood hormone levels during the immune response. Proc Soc Exp Biol Med 1975; 150:466–470
  42. Sapolsky R, Rivier C, Yamamoto G, Plotsky P, Vale WW: Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 1987; 238:522– 524
  43. Bernton EW, Beach JE, Holaday JW, Smallridge RC, Fein HGZ: Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. Science 1987; 238:519–52
  44. Besedovsky H, del Rey A, Sorkin E, Da Prada M, Burri R, Honegger C: Cytokines as modulators of the hypothalamus-pituitary-adrenal axis. J Steroid Biochem Mol Biol 1991; 40:613–618
  45. Rivier C: Neuroendocrine effects of cytokines in the rat. Rev Neurosci 1993; 4:223–237
  46. Rivest S, Rivier C: Centrally injected interleukin-1b inhibits the hypothalamic LHRH secretion and circulating LH levels via prostaglandins in rats. J Neuroendocrinol 1993; 5:445–450
  47. Krueger JM, Majde JA: Microbial products and cytokines in sleep and fever regulation. CRC Crit Rev Immunol 1994; 14:355–379
  48. Moldofsky H, Lue FA, Eisen J, Keystone E, Gorczynski RM: The relationship of interleukin-1 and immune functions to sleep in humans. Psychosom Med 1986; 48:309–318
  49. Lue FA, Bail M, Jephthah-Ochola J, Carayanniotis K, Gorczynski R, Moldofsky H: Sleep and cerebrospinal fluid interleukin-1-like activity in the cat. Int J Neurosci 1988; 42:179–183
  50. Krueger JM: Somnogenic activity of immune response modifiers. Trends Pharmacol Sci 1990; 11:122–126
  51. Plata-Salaman CR, Sonti G, Borkoski JP, Wilson CD: Anorexia induced by chronic central administration of cytokines at estimated pathophysiological concentrations. Physiol Behav 1996; 60:867–875
  52. Bessler H, Karp L, Notti I, Apter A, Tynus S, Djaldetti M, Weizman R: Cytokine production in anorexia nervosa. Clin Neuropharmacol 1993; 16:237–243[Medline]
  53. Persoons JH, Schornagel K, Breve J, Berkenbosch F, Kraal G: Acute stress affects cytokines and nitric oxide production by alveolar macrophages differently. Am J Respir Crit Care Med 1995; 152:619–624
  54. Glaser R, Rice J, Speicher CE, Stout JC, Kiecolt-Glaser JK: Stress depresses interferon production by leukocytes concomitant with a decrease in NK cell activity. Behav Neurosci 1986; 100:675–678
  55. Glaser R, Kennedy S, Lafuse WP, Bonneau RH, Speicher C, Hillhouse J, Kiecolt-Glaser JK: Psychological stress-induced modulation of interleukin 2 receptor gene expression and interleukin 2 production in peripheral blood leukocytes. Arch Gen Psychiatry 1990; 47:707–712
  56. Dobbin JP, Harth M, McCain GA, Martin RA, Cousin K: Cytokine production and lymphocyte transformation during stress. Brain Behav Immun 1991; 5:339–348
  57. Mittwoch-Jaffe T, Shalit F, Srendi B, Yehuda S: Modification of cytokine secretion following mild emotional stimuli. Neuroreport 1995; 6:789–792
  58. Kiecolt-Glaser JK, Marucha PT, Malarkey WB, Mercado AM, Glaser R: Slowing of wound healing by psychological stress. Lancet 1995; 346:1194–1196
  59. Decker D, Schondorf M, Bidlingmaier F, Hirner A, von Ruecker AA: Surgical stress induces a shift in the type-1/type-2 T-helper cell balance, suggesting down-regulation of cell-mediated and up-regulation of antibody-mediated immunity commensurate to the trauma. Surgery 1996; 119:316–325
  60. Nakano Y, Nakamura S, Hirata M, Harada K, Ando K, Tabuchi T, Matunaga I, Oda H: Immune function and lifestyle of taxi drivers in Japan. Ind Health 1998; 36:32–39
  61. Maes M, Song C, Lin A, De Jongh R, Van Gastel A, Kenis G, Bosmans E, De Meester I, Benoy I, Neels H, Demedts P, Janca A, Scharpe S, Smith RS: The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 1998; 10:313–318
  62. Ackerman KD, Martino M, Heyman R, Moyna NM, Rabin BS: Stressor-induced alteration of cytokine production in multiple sclerosis patients and controls. Psychosom Med 1998; 60:484–491
  63. Marshall GD, Agarwal SK, Lloyd C, Cohen L, Henninger EM, Morris GJ: Cytokine dysregulation associated with exam stress in healthy medical students. Brain Behav Immun 1998; 12:297–307
  64. Glaser R, Kiecolt-Glaser JK, Marucha PT, MacCallum RC, Laskowski BF, Malarkey WB: Stress-related changes in proinflammatory cytokine production in wounds. Arch Gen Psychiatry 1999; 56:450–456
  65. Maes M, Bosmans E, Meltzer HY, Scharpé S, Suy E: Interleukin-1b: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993; 150:1189– 1193
  66. Maes M, Meltzer H, Bosmans E, Bergmans R, Vandoolaeghe E, Rajan R, Desnyder R: Increased plasma concentrations of interleukin-6, soluble interleukin-6 receptor, soluble interleukin-2 receptor and transferrin receptor in major depression. J Affect Disord 1995; 34:301–309
  67. Weizman R, Laor N, Podliszewski E, Notti I, Djaldetti M, Bessler H: Cytokine production in major depressed patients before and after clomipramine treatment. Biol Psychiatry 1994; 35:42–47[
  68. Kronfol Z, Singh VJ, Zhang Q: Plasma cytokines, acute phase proteins and cortisol in major depression (abstract). Biol Psychiatry 1995; 37(suppl):609A
  69. Kronfol Z, House JD: Lymphocyte mitogenesis, immunoglobulin and complement levels in depressed patients and normal controls. Acta Psychiatr Scand 1989; 80:142–167
  70. Maes M, Smith RS: Fatty acids, cytokines, and major depression. Biol Psychiatry 1998; 43:313–314
  71. Ganguli R, Rabin BS, Kelly RH, Lyte M, Ragu U: Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann NY Acad Sci 1987; 496:676–685
  72. Villemain F, Chatenoud L, Galinowski A, Homo-Delarche F, Ginestet D, Loo H, Zarifian E, Bach J-F: Aberrant T-cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am J Psychiatry 1989; 146:609–616
  73. Ganguli R, Brar JS, Chengappa KR, Deleo M, Yang ZW: Mitogen-stimulated interleukin 2 production in never-medicated first episode schizophrenics—the influence of age of onset and negative symptoms. Arch Gen Psychiatry 1995; 52:668–672
  74. Rapaport MH, Torrey EF, McAllister CG, Nelson DL, Pickar D, Paul SM: Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins. Eur Arch Psychiatr Clin Neurosci 1993; 243:7–10
  75. Ganguli R, Young Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV, Rabin BS: Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatr Res 1994; 51:1–10[
  76. Aisen PS, Davis KL: Inflammatory mechanisms in Alzheimer’s disease: implications for therapy. Am J Psychiatry 1994; 151:1105–1113
  77. Matsubara E, Hirrai S, Amari M, Shoji M, Yamaguchi H, Okomoto K, Ishiguro K, Harigaya Y, Wakabayashi K: Alpha-1-antichymotripsin as a possible biochemical marker for Alzheimer-type dementia. Ann Neurol 1990; 28:561–567
  78. Abraham CR, Selkor DJ, Potter H: Immunohistochemical identification of the serum protein inhibitor alpha-1 antichymotripsin in the brain amyloid deposits of Alzheimer’s disease. Cell 1988; 52:487–501
  79. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL III, Araoz C: Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989; 86:7611–7615
  80. Bauer J, Gauter U, Strauss S, Stadtmuller G, Frommberger U, Bauer H, Volk B, Berger M: The participation of interleukin-6 in the pathogenesis of Alzheimer’s disease. Res Immunol 1992; 143:650–657
  81. Altstiel L, Sperber K: Cytokines in Alzheimer’s disease. Prog Neuropychopharmacol Biol Psychiatry 1991; 15:481–495
  82. Brambilla F, Bellodi L, Perna G, Bertani A, Panerai A, Sacerdote P: Plasma interleukin-1b concentrations in panic disorder. Psychiatry Res 1994; 54:135–142
  83. Brambilla F, Perna G, Bellodi L, Arancio C, Bertani A, Perini G, Carraro C, Gava F: Plasma interleukin-1b and tumor necrosis factor concentrations in obsessive-compulsive disorders. Biol Psychiatry 1997; 42:976–981
  84. Warren RP: An immunologic theory for the development of some cases of autism. CNS Spectrums 1998; 3:71–79
  85. Dusheiko G: Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26:1125–1215
  86. Schiller JH, Storer BE, Witt PL, Alberti D, Tombes MB, Arzoomanian R, Proctor RA, McCarthy D, Brown RR, Voss SD, Remick SC, Grem JL, Borden EC, Trump DL: Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. Cancer Res 1991; 51:1651–1658
  87. Rosenberg SA: The development of new immunotherapies for the treatment of cancer using interleukin-2: a review. Ann Surg 1988; 208:121–135
  88. Renault PF, Hoofnagle JH, Park H, Mullen ED, Peters M, Jones B, Rustgi V, Jonas EA: Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med 1987; 147:1577–1580
  89. Stritz D, Valentine AD, Meyers CA: Manic episodes in two patients treated with interferon alpha. J Neuropsychiatr Clin Neurosci 1997; 9:273–276
  90. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW: Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21:241–243
  91. Levenson J, Fallon HJ: Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993; 88:760–761[
  92. Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA: The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987; 107:293–300
  93. Klingemann HG: Clinical applications of recombinant human colony stimulating factors. Can Med Assoc J 1989; 140:137–142
  94. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253–259[
  95. Rogler G, Andus T: Cytokines in inflammatory bowel disease. World J Surg 1998; 22:382–389
  96. Norris JG, Benveniste EN: Interleukin-6 production by astrocytes: induction by the neurotransmitter norepinephrine. J Neuroimmunol 1993; 45:137–146
  97. Schleuning MJ, Duggan A, Reem GH: Inhibition by chlorpromazine of lymphokine-specific m-RNA expression in human thymocytes. Eur J Immunol 1989; 19:1491–1496
  98. Bertini S, Garattini R, Delgado P, Ghezzi P: Pharmacological activities of chlorpromazine involved in the inhibition of tumor necrosis factor production in vivo in mice. Immunology 1993; 79:217–219
  99. Maes M, Meltzer HY, Bosmans E: Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994; 89:346–351
  100. Sperner-Unterweger B, Gaggl S, Fleischhacker WW, Barnas C, Herold M, Geissler D: Effects of clozapine on hematopoiesis and the cytokine system. Biol Psychiatry 1993; 34:536–543
  101. Song C, Leonard E: An acute phase protein response in the olfactory bulbectomised rat: effect of sertraline treatment. Med Sci Res 1994; 22:313–314
  102. Kronfol Z, LeMay L, Nair M, Kluger M: Electroconvulsive therapy increases plasma levels of interleukin-6. Ann NY Acad Sci 1990; 594:463–465


Tinggalkan Balasan

Isikan data di bawah atau klik salah satu ikon untuk log in:

Logo WordPress.com

You are commenting using your WordPress.com account. Logout /  Ubah )

Foto Google

You are commenting using your Google account. Logout /  Ubah )

Gambar Twitter

You are commenting using your Twitter account. Logout /  Ubah )

Foto Facebook

You are commenting using your Facebook account. Logout /  Ubah )

Connecting to %s